Mueller M, Hoermandinger C, Richter G, et al. - Assessment of outcome and reliability of the HeartWare HVAD (HW) and HeartMate 3 (HM3) left ventricular assist devices has been performed in various trials. Researchers sought to perform a direct comparison of clinical outcomes and of the complication profile of these 2 left ventricular assist devices via performing a retrospective analysis of patients supported with HM3 and HW as a left ventricular assist device. They assessed 100 patients who underwent implantation of the HW and 100 patients who underwent implantation of the HM3. Per data gained, the 2 pumps differ in the complication profile. Among HW patients vs HM3 patients, 73% vs 57%, respectively, were rated as having an INTERMACS level I or II and 14 vs 4 patients, respectively, had pre-, intra- or post-pump blood flow obstruction. Among HW patients, there were more frequent cerebral bleeding and significantly higher incidence of haemocompatibility-related adverse events. However, the groups exhibited comparable survival outcome.